Predict your next investment

CONSUMER PRODUCTS & SERVICES | Personal / Personal Care Products
solutex.es

See what CB Insights has to offer

Stage

Grant | Alive

Total Raised

$3.01M

Last Raised

$3.01M | 17 yrs ago

About Solutex

Developer of flavor and fragrances, functional ingredients, and nutraceutical products.

Solutex Headquarter Location

C/Arbellones, 7

E-50290,

Spain

34 91 806 0477

Latest Solutex News

Noventure signs exclusive license agreement for innovative food supplement EPA3G

Feb 17, 2021

Noventure signs exclusive license agreement for innovative food supplement EPA3G Barcelona, Spain, February 17, 2021 – Noventure announces today that it has signed an exclusivity agreement for the licensing of the innovative food supplement EPA3G, with global partner Azur – a division of Solutex (Madrid, Spain). Within the marketplace, there is a huge offering in omega-3 supplements. There is much debate on the amount of omega-3 required to deliver meaningful health benefits and on what is a realistic dosage to suit everyday lifestyles. The current options of multiple servings, or those bulky, difficult-to-swallow capsules, are not ideal. EPA3G successfully fills this market gap. With almost three grams of pure EPA (eicosapentaenoic acid) in one easy-to-take daily dose, EPA3G is a patented, state-of-the-art drinkable emulsion available in sachets, with excellent texture, taste and scent. Under the terms of the agreement, Noventure has the rights to license EPA3G to specialized companies. These must have marketing expertise and knowledge in the commercialization of high-end food supplements. The agreement covers over 50 countries on different continents, including all EU members and associated states, the UK, the Balkans, Russia, Ukraine, Eurasian countries, Mexico, Taiwan and several African states. The financial terms of the agreement have not been disclosed. “Noventure’s mission is to shape innovative science assets and bring them to markets around the world. With this agreement, people will now have a differentiated, value-added omega-3 product, which is effective and easy to use,” said Luciano Conde, CEO of Noventure. “We are very pleased to work with Azur, together we will keep building strong partnerships based on a shared understanding of user’s needs and pursue market opportunities whilst growing together.”   “Globally, EPA is gaining importance and becoming a part of many consumer’s daily diet [i] . The key reasons for this market growth have been the increased prevalence of lifestyle diseases and people choosing preventive healthcare measures,” said Julio Boza, CEO of Azur. “Consumer desire for high effectiveness and bioavailability has also ensured manufacturers seek more highly concentrated forms to better provide efficacious doses of EPA. We are delighted to work with Noventure. We believe this technology will allow people to satisfy their omega-3 requirements in a convenient drinkable format. This is a great example of transforming bright science and technology into breakthrough, sustainable commercial solutions and is an example of how to work and grow together.”   The global EPA and DHA market is projected to grow at the CAGR of 8.26% during forecast period 2020 – 2025. About Azur Global Nutrition/Solutex Azur Global Nutrition develops and delivers unique, science-backed and data driven value-added products to the marketplace through extensive research and innovation specific to immune-nutrition. Azur offers ingredients, dietary supplements and medical food products derived from omega-3 ingredients and focused on balancing the lipid metabolism and homeostasis of the body for health and wellness. Azur is a division of the Solutex Group, a biotechnology industry leader in the manufacture and commercialization of premium highly concentrated omega-3 fatty acids.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Solutex

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Solutex is included in 1 Expert Collection, including Advanced Materials.

A

Advanced Materials

1,209 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.

Solutex Patents

Solutex has filed 9 patents.

The 3 most popular patent topics include:

  • Fatty acids
  • Immunology
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/8/2019

8/3/2021

Fatty acids, G protein coupled receptors, Eicosanoids, Immunology, Cell biology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/8/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/3/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Fatty acids, G protein coupled receptors, Eicosanoids, Immunology, Cell biology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.